Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis

Table 3

Adverse events reported in all patients treated with dimethyl fumarate.

	Dimethyl fumarate, N = 71
Patients with at least one adverse event, n (%)	63 (88.2%)
The proportion of patients with an adverse event, n (%)
Flushing	52 (73.2%)
Pruritus	12 (16.9%)
Abdominal pain	12 (16.9%)
Liver dysfunctional test	11 (15.4%)
Nausea	11 (15.4%)
Dry mouth	9 (12.6%)
Diarrhea	9 (12.6%)
Itching	8 (11.2%)
Weight loss	7 (9.8%)
Dyspnea	3 (4.2%)
Palpitation	1 (1.4%)
Tremor	1 (1.4%)
Hair loss	1 (1.4%)
Depression	1 (1.3%)